Global Hormone Replacement Therapy Market is expected to reach US$ 25.09 Billion by 2027 according to the publisher. Over the years, hormone replacement therapy has been widely used to treat disorders associated with Menopause in women, which has positively influenced the reduction of hot flashes, risks of osteoporosis, and other menopause symptoms. Certain factors positively affecting the growth of hormone replacement therapy (HRT) are increasing awareness of postmenopausal issues among women, hormonal imbalance disorders with the rising geriatric population, and a rise in drug development with novel delivery systems.Hormone Replacement Therapy Market size was US$ 18.04 Billion in 2022. Industry Trends By Product, Application, End User, Impact of Inflation, Company Analysis, Global Forecast 2023-2027
According to the UN, the global population will grow by 8.5 billion in 2030 and 9.7 billion in 2050. Common problems include weight gain, fatigue, memory decline, low libido, aging appearance, and muscle loss. However, the dangers of HRT vary with the Type, dose, and route of administration, use duration, and initiation age. As per this research study, The global hormone replacement therapy market size was US$ 18.04 Billion in 2022.
Type of Hormone Replacement Therapy
Based on Type, hormone replacement therapy is categorized into Estrogen, Human Growth, Thyroid, Testosterone, and Progestogen. Estrogen & progesterone replacement therapy dominated the HRT market. It continues to maintain its dominance in the future due to high demand due to the increasing number of women reaching Menopause. In addition, Estrogen plus progesterone therapy has a small increased risk of breast cancer, which is more significant with synthetic progestins. Hormone Replacement Therapy Industry is likely to grow with a CAGR of 6.82% during 2022-2027.Disease Type of Hormone Replacement Therapy
Based on Disease type, Menopause will emerge as a significant disease segment for the colonoscopy devices industry. The rising number of women aged 45 to 60 years and the increasing incidence of vasomotor symptoms that may lead to severe conditions, such as osteoporosis, are projected to fuel market growth. As per the American Congress of Obstetricians and Gynecologists, around 6,000 ladies arrive at Menopause every day. In Sept 2021, Theramex announced the approval of Bijuva/Bijuve across Europe, body-identical HRT for estrogen deficiency symptoms in postmenopausal women with an intact uterus at least one year since last menses, which combines progesterone and estradiol in a single daily oral capsule.The Route of Administration of Hormone Replacement Therapy
Based on the route of administration, the oral category dominated the market in 2022 owing to the rise in prescription rate. Around 120 million prescriptions of Levothyroxine sodium tablets are dispensed annually in the U.S. Parenteral is expected to witness the fastest growth. In addition, developing and approving long-acting products are expected to boost segment growth. For instance, in October 2021, Pfizer, Inc. received approval for its NGENLA (somatrogon), a once-a-week long-acting recombinant human growth hormone, from Health Canada to treat a patient with growth hormone deficiency.Region Insights - Hormone Replacement Therapy Market
North America ruled the general market for hormone replacement therapy, owing to the growth hormone deficiency disorders and rise in the prevalence of Menopause and also high awareness of the therapy amongst the age group of 35 years and above patients. In addition, the Availability of advanced product launches of various treatments boosted the North American market.Europe is the another most dominant region, owing to the geriatric population suffering from hypothyroidism, a surge in hormonal disorders in women suffering from menopausal symptoms, and a rise in growth hormone disorders. For instance, according to Frontier, in June 2021, the prevalence of thyroid disorders ranged from 0.2-5.3% in Europe. Thus, this is leading to an increase in demand for thyroid replacement therapies in Europe, further boosting the market growth in the region.
Asia Pacific is supposed to observe the quickest development over the forecast period. Expanding mindfulness levels and rising focal points of medical services suppliers on the destruction of hormonal lacks are supposed to help the market's growth inside the locale.
The market in Latin America and Middle East & Africa is expected to grow slower owing to the unmet needs of these therapies, low awareness among the population, reduced healthcare expenditure, and others. For instance, according to the National Library of Medicine, in December 2021, the prevalence of menopausal hormone therapy was 12.5% in these regions, which is still lower compared to the other areas globally. Furthermore, the launch of new products in this region by various key players may fuel the subsequent growth of the market.
Key Companies & Market Share Insights
Major global hormone replacement therapy players include Merck KgaA, Bayer AG, Pfizer Inc., Abbott Laboratories, Novartis AG, Novo Nordisk A/S, Amgen, Inc., F. Hoffmann-La Roche, and Eli Lilly and Company. In 2021, I-MAB Biopharma Co., Ltd. entered into a collaboration with Jumpcan Pharmaceutical Group for the development & commercialization of eftansomatropin alfa (TJ101) in China.The publisher's latest report “Global Hormone Replacement Therapy Market, by Type (Estrogen, Human Growth, Thyroid, Progestogen and Testosterone), by Route of Administration (Oral, Parenteral, Transdemal and Others), by Disease type (Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, and Others), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) and Company (Merck KgaA, Bayer AG, Pfizer Inc., Abbott Laboratories, Novartis AG, Novo Nordisk A/S, Amgen, Inc., F. Hoffmann-La Roche, and Eli Lilly and Company)” provides comprehensive details about Global Hormone Replacement Therapy Industry.
Type Outlook: Market has been covered from 5 viewpoints
1. Estrogen2. Progesterone
3. Human Growth
4. Thyroid
5. Testosterone
Route of Administration Outlook: Market has been covered from 4 viewpoints
1. Oral2. Parenteral
3. Transdermal
4. Others
Disease Type Outlook: Market has been covered from 5 viewpoints
1. Menopause2. Hypothyroidism
3. Male Hypogonadism
4. Growth Hormone Deficiency
5. Others
Regional Outlook: Market has been covered from 5 viewpoints
1. North America2. Europe
3. Asia Pacific
4. South America
5. Middle East & Africa
All companies have been covered into 3 viewpoints
- Overview
- Recent Developments
- Revenues
Key Players Analysis
1. Merck KgaA2. Bayer AG
3. Pfizer Inc.
4. Abbott Laboratories
5. Novartis AG
6. Novo Nordisk A/S
7. Amgen, Inc.
8. F. Hoffmann-La Roche
9. Eli Lilly and Company
Table of Contents
Companies Mentioned
- Merck KgaA
- Bayer AG
- Pfizer Inc.
- Abbott Laboratories
- Novartis AG
- Novo Nordisk A/S
- Amgen, Inc.
- F. Hoffmann-La Roche
- Eli Lilly and Company
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...